AR035560A1 - Una composicion polipeptida, y de adhesion, un acido nucleico, una celula, un antagonista, un metodo para producir un complejo de antigeno anticuerpo, usos de la composicion polipeptida o de adhesion, un metodo para formar la composicion polipeptida, un metodo para rastrear un receptor, y equipos qu - Google Patents
Una composicion polipeptida, y de adhesion, un acido nucleico, una celula, un antagonista, un metodo para producir un complejo de antigeno anticuerpo, usos de la composicion polipeptida o de adhesion, un metodo para formar la composicion polipeptida, un metodo para rastrear un receptor, y equipos quInfo
- Publication number
- AR035560A1 AR035560A1 ARP000104753A ARP000104753A AR035560A1 AR 035560 A1 AR035560 A1 AR 035560A1 AR P000104753 A ARP000104753 A AR P000104753A AR P000104753 A ARP000104753 A AR P000104753A AR 035560 A1 AR035560 A1 AR 035560A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- composition
- primate
- amino acids
- contiguous amino
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 21
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 21
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 21
- 239000000203 mixture Substances 0.000 title abstract 19
- 102000039446 nucleic acids Human genes 0.000 title abstract 6
- 108020004707 nucleic acids Proteins 0.000 title abstract 6
- 150000007523 nucleic acids Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 239000002131 composite material Substances 0.000 title 1
- 241000288906 Primates Species 0.000 abstract 9
- 150000001413 amino acids Chemical class 0.000 abstract 8
- 210000004027 cell Anatomy 0.000 abstract 5
- 239000003814 drug Substances 0.000 abstract 3
- 230000035479 physiological effects, processes and functions Effects 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000005406 washing Methods 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 108700012920 TNF Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000000240 adjuvant effect Effects 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 230000014828 interferon-gamma production Effects 0.000 abstract 1
- 210000003071 memory t lymphocyte Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Abstract
La composición polipéptida comprende: a) ambos: i) un polipéptido sustancialmente puro que comprende una pluralidad de distintos segmentos de por lo menos 7 aminoácidos contiguos de IL-12 p40; y ii) un polipéptido sustancialmente puro que comprende una pluralidad de distintos segmentos de por lo menos 7 aminoácidos contiguos de IL-B30; b) ambos: i) un polipéptido sustancialmente puro que comprende por lo menos 11 aminoácidos contiguos de IL-12 p40, y ii) un polipéptido sustancialmente puro que comprende por lo menos 11 aminoácidos contiguos de IL-B30; c) un polipéptido sustancialmente puro que comprende a ambos: i) una pluralidad de segmentos distintos de por lo menos 7 aminoácidos contiguos de IL-12 p40; y ii) una pluralidad de segmentos distintos de por lo menos 7 aminoácidos contiguos de IL-B30; o d) un polipéptido sustancialmente puro que comprende ambos: i) un segmento de por lo menos 11 aminoácidos contiguos de IL-12 p40; y ii) un segmento de por lo menos 11 amino ácidos contiguos de IL-B30. La composición de adhesión comprende un sitio de adhesión de antígeno de un anticuerpo que se adhiere específicamente a la composición polipéptida pero no a cualquiera de un polipéptido IL-12 p40 o un polipéptido IL-B30 solo. El ácido nucleico aislado o recombinante codifica la composición polipéptida. El ácido nucleico que hibridiza con la composición polipéptida comprende la porción codificadora, madura, natural de IL-12 p40 de primate y la porción codificadora, madura, natural de IL-B30 de primate donde dicho ácido nucleico hibridiza: a) bajo condiciones de lavado de 30 minutos a 50°C y menos de una sal 1M para una porción codificadora madura natural de IL-12 p40 de primate; y b) bajo condiciones de lavado de 30 minutos a 50°C y de menos de una sal 1M para la porción codificadora madura natural de primate IL-B30. La célula comprende dicho ácido nucleico aislado o recombinante. El antagonista de la composición polipéptida, que no es un polipéptido IL-12 p40 o un polipéptido IL-B30 solo, se combina con: a) un antagonista TNFa; b) un antagonista IL-12; c) IL-10; o d) esteroides. El método para producir un complejo de antígeno anticuerpo comprende poner en contacto bajo condiciones apropiadas, una composición IL-12 p40/IL-B30 de primate con un anticuerpo de la composición de adhesión permitiendo de este modo que se forme el complejo. Los usos de la composición polipéptida o de la composición de adhesión, para la preparación de un medicamento para modular la fisiología o el desarrollo de una célula o tejido; para la preparación de un medicamento para modular la fisiología o el desarrollo de una célula que resulta en un incremento en la producción de IFNg; para modular la fisiología o el desarrollo de una célula en un organismo huésped, donde dicha modulación da como resultado: a) un efecto anti-tumoral; b) un efecto coadyuvante; c) un efecto anti-viral; o d) un efecto alérgico antagonizado; para modular la respuesta inflamatoria en un animal; para la preparación de un medicamento para inducir la proliferación de células T de memoria. El método para formar la composición polipéptida, comprende incrementar la secreción de: a) un IL-B30 de primate que comprende la expresión de dicho IL-B30 de primate con IL-12 p40; o b) un IL-12 p40 de primate que comprende la expresión de dicho IL-12 p40 de primate con IL-B30. El método para rastrear un receptor que se adhiere a la composición polipéptida, comprende poner en contacto dicha composición con una célula que expresa dicho receptor bajo condiciones que permiten que la composición se adhiera a dicho receptor, formando de esta manera una interacción detectable. El equipo comprende la composición polipéptida, al ácido nucleico aislado o recombinante, o a la composición de adhesión, y un compartimento que comprende dichas composiciones o ácido.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39309099A | 1999-09-09 | 1999-09-09 | |
| US16461699P | 1999-11-10 | 1999-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035560A1 true AR035560A1 (es) | 2004-06-16 |
Family
ID=26860707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000104753A AR035560A1 (es) | 1999-09-09 | 2000-09-11 | Una composicion polipeptida, y de adhesion, un acido nucleico, una celula, un antagonista, un metodo para producir un complejo de antigeno anticuerpo, usos de la composicion polipeptida o de adhesion, un metodo para formar la composicion polipeptida, un metodo para rastrear un receptor, y equipos qu |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1210434B2 (es) |
| JP (6) | JP4505166B2 (es) |
| KR (1) | KR100894359B1 (es) |
| CN (1) | CN100529076C (es) |
| AR (1) | AR035560A1 (es) |
| AT (1) | ATE389019T1 (es) |
| AU (2) | AU780163B2 (es) |
| CA (1) | CA2388562C (es) |
| DE (1) | DE60038304T3 (es) |
| ES (1) | ES2300276T5 (es) |
| HK (1) | HK1044170B (es) |
| HU (1) | HU230679B1 (es) |
| IL (1) | IL148300A0 (es) |
| MX (1) | MXPA02002684A (es) |
| WO (1) | WO2001018051A2 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007202362B2 (en) * | 1999-09-03 | 2011-06-23 | Merck Sharp & Dohme Corp. | Mammalian receptor proteins; related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| ES2307618T3 (es) | 2000-05-10 | 2008-12-01 | Schering Corporation | Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados. |
| CA2501786C (en) | 2002-10-30 | 2015-02-17 | Genentech, Inc. | Inhibition of il-17 production |
| ES2367302T3 (es) | 2002-12-23 | 2011-11-02 | Schering Corporation | Usos de la citoquina il-23 de mamífero; reactivos relacionados. |
| ES2330220T3 (es) | 2003-03-10 | 2009-12-07 | Schering Corporation | Usos de antagonistas de il-23; reactivos relacionados. |
| CN101052726A (zh) | 2003-05-09 | 2007-10-10 | 森托科尔公司 | IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途 |
| EP1522858A1 (en) * | 2003-10-10 | 2005-04-13 | Jean-Christophe Roegel | Methods for selecting compounds using antibodies with activity as agonist, antagonist or allosteric modulators |
| WO2005108425A1 (en) * | 2004-05-10 | 2005-11-17 | Cytos Biotechnology Ag | Il-23 p19 antigen array and uses thereof |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| US7820168B2 (en) | 2004-12-20 | 2010-10-26 | Schering Corporation | Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17 |
| CA2613818C (en) | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| PL1937721T3 (pl) | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
| SG165322A1 (en) | 2005-08-31 | 2010-10-28 | Schering Corp | Engineered anti-il-23 antibodies |
| EA035459B1 (ru) | 2005-12-29 | 2020-06-19 | Сентокор, Инк. | Антитело против il-23p19 |
| WO2007076933A1 (en) | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Interleukin-12p40 variants with improved stability |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Ｉｌ-２３拮抗劑於治療感染之用途 |
| EP2426145B1 (en) | 2007-02-23 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23p19 antibodies |
| PL2426144T3 (pl) | 2007-02-23 | 2019-05-31 | Merck Sharp & Dohme | Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej |
| WO2008106131A2 (en) | 2007-02-28 | 2008-09-04 | Schering Corporation | Combination therapy for treatment of immune disorders |
| EP2395025A1 (en) | 2007-02-28 | 2011-12-14 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
| JP2011504740A (ja) | 2007-11-27 | 2011-02-17 | アブリンクス エン．ヴェー． | ヘテロ二量体サイトカイン及び／又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド |
| JPWO2009133863A1 (ja) * | 2008-04-28 | 2011-09-01 | 国立大学法人浜松医科大学 | Ｅｐ１アゴニストを含有してなる免疫増強剤 |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| JP6126532B2 (ja) | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗ｉｌ−２３抗体 |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| US9512194B2 (en) | 2012-01-27 | 2016-12-06 | The Board Of Trustees Of The Leland Stanford Junior University | Modified IL-13 polypeptides |
| CN109206516A (zh) | 2012-05-03 | 2019-01-15 | 勃林格殷格翰国际有限公司 | 抗IL-23p19抗体 |
| US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| WO2014171721A1 (ko) * | 2013-04-16 | 2014-10-23 | 가톨릭대학교 산학협력단 | 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도 |
| KR101625112B1 (ko) | 2013-04-16 | 2016-05-27 | 가톨릭대학교 산학협력단 | 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도 |
| JP6936934B2 (ja) | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | インターロイキン−４受容体結合融合タンパク質及びその使用 |
| US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
| TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
| JP6219875B2 (ja) * | 2015-04-10 | 2017-10-25 | 株式会社スクウェア・エニックス | ネットワークゲームシステム、ゲーム装置及びプログラム |
| BR112019022873A8 (pt) | 2017-05-02 | 2023-04-11 | Merck Sharp & Dohme | Formulação, e, vaso ou dispositivo de injeção. |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2019383017A1 (en) | 2018-11-20 | 2021-06-03 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
| CA3138241A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| CN114317430A (zh) * | 2021-12-28 | 2022-04-12 | 河北银丰鼎诚生物技术有限公司 | 一种适用于脐血来源免疫细胞扩增的培养液 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0790308T3 (da) * | 1989-12-22 | 2007-10-08 | Hoffmann La Roche | Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod |
| DE4315127A1 (de) * | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
| US5851523A (en) * | 1994-03-24 | 1998-12-22 | Ludwig Institute For Cancer Research. | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof |
| US5853721A (en) * | 1995-01-31 | 1998-12-29 | Hoffmann-La Roche Inc. | Antibody to interleukin-12 receptor |
| CA2268365A1 (en) * | 1996-10-18 | 1998-04-30 | Jeff Nordstrom | Il-12 gene expression and delivery systems and uses |
| CO4810232A1 (es) * | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
| AU2661199A (en) * | 1998-02-06 | 1999-08-23 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
-
2000
- 2000-09-08 DE DE60038304.0T patent/DE60038304T3/de not_active Expired - Lifetime
- 2000-09-08 CA CA2388562A patent/CA2388562C/en not_active Expired - Lifetime
- 2000-09-08 MX MXPA02002684A patent/MXPA02002684A/es active IP Right Grant
- 2000-09-08 AU AU73608/00A patent/AU780163B2/en not_active Expired
- 2000-09-08 JP JP2001522273A patent/JP4505166B2/ja not_active Expired - Lifetime
- 2000-09-08 WO PCT/US2000/024686 patent/WO2001018051A2/en active IP Right Grant
- 2000-09-08 AT AT00961688T patent/ATE389019T1/de not_active IP Right Cessation
- 2000-09-08 IL IL14830000A patent/IL148300A0/xx active IP Right Grant
- 2000-09-08 EP EP00961688.9A patent/EP1210434B2/en not_active Expired - Lifetime
- 2000-09-08 KR KR1020027003089A patent/KR100894359B1/ko active IP Right Grant
- 2000-09-08 ES ES00961688.9T patent/ES2300276T5/es not_active Expired - Lifetime
- 2000-09-08 CN CNB008154007A patent/CN100529076C/zh not_active Expired - Lifetime
- 2000-09-08 HU HU0301102A patent/HU230679B1/hu unknown
- 2000-09-11 AR ARP000104753A patent/AR035560A1/es unknown
-
2002
- 2002-07-10 HK HK02105118.4A patent/HK1044170B/zh not_active IP Right Cessation
-
2006
- 2006-08-28 JP JP2006231402A patent/JP2007045830A/ja not_active Withdrawn
-
2008
- 2008-10-31 AU AU2008240348A patent/AU2008240348B2/en not_active Expired
-
2009
- 2009-06-19 JP JP2009147075A patent/JP4969610B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-21 JP JP2010098317A patent/JP2010233571A/ja not_active Withdrawn
-
2013
- 2013-03-01 JP JP2013040389A patent/JP2013128489A/ja active Pending
-
2014
- 2014-10-07 JP JP2014206652A patent/JP6140122B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035560A1 (es) | Una composicion polipeptida, y de adhesion, un acido nucleico, una celula, un antagonista, un metodo para producir un complejo de antigeno anticuerpo, usos de la composicion polipeptida o de adhesion, un metodo para formar la composicion polipeptida, un metodo para rastrear un receptor, y equipos qu | |
| EP0399816B1 (en) | Purification and characterization of a glioma-derived growth factor | |
| Hance et al. | Rigid control of synthesis of collagen types I and III by cells in culture | |
| Rifas et al. | Macrophage-derived growth factor for osteoblast-like cells and chondrocytes. | |
| Younai et al. | Modulation of collagen synthesis by transforming growth factor-β in keloid and hypertrophic scar fibroblasts | |
| Tachibana et al. | Rapid fabrication of keratin–hydroxyapatite hybrid sponges toward osteoblast cultivation and differentiation | |
| ATE187458T1 (de) | Peptidverbindungen mit wachstumsfaktorähnlicher aktivität | |
| ES2119250T3 (es) | Composiciones y metodos para estimular el crecimiento y diferenciacion de megacariocitos. | |
| Marchbank et al. | Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects | |
| Wojciak et al. | The accumulation of inflammatory cells in synovial sheath and epitenon during adhesion formation in healing rat flexor tendons | |
| DE68929402D1 (de) | Verfahren zur herstellung von wasserlöslichen polypeptiden | |
| DE69329903D1 (de) | Bioabbaubare polymere zur zelltransplantation | |
| DE93619T1 (de) | Plasminogenaktivator fuer menschliches gewebe, diesen aktivator enthaltende pharmazeutische zusammensetzungen, verfahren zur herstellung des aktivators sowie dna und transformierte zellzwischenprodukte hierfuer. | |
| DeLuca et al. | Altered glycoprotein synthesis in mouse epidermal cells treated with retinyl acetate in vitro | |
| Armstrong et al. | Punch biopsy wounds treated with Monsel's solution or a collagen matrix: a comparison of healing | |
| EP0443224B1 (en) | Use of thrombospondin to promote wound healing | |
| Edwards et al. | Macrophage secretory products selectively stimulate dermatan sulfate proteoglycan production in cultured arterial smooth muscle cells. | |
| EP0513201A1 (en) | Leukocyte-derived growth factor | |
| Gohda et al. | Biological and immunological properties of human hepatocyte growth factor from plasma of patients with fulminant hepatic failure | |
| ATE299187T1 (de) | Modifizierter humaner granulozyten-kolonie stimulierenderfaktor sowie verfahren zur herstellung desselben | |
| Weiss et al. | Un‐cross‐linked fibrin substrates inhibit keratinocyte spreading and replication: Correction with fibronectin and factor XIII cross‐linking | |
| ATE275626T1 (de) | Verfahren zur herstellung von rekombinanten menschlichen lh-rh rezeptor proteinen in spezifischen cho zellinien. | |
| Smith | Recovery and tissue repair | |
| PT81372A (fr) | Composition anti-bacterienne et procede de preparation de ses constituants actifs | |
| ES2682299T3 (es) | Composición farmacéutica destinada al tratamiento de las patologías ortopédicas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |